Date:7/29/2009

NSOLIDATED STATEMENTS OF OPERATIONS Three months ended Six months ended June 30, June 30, ------------------ ------------------ 2009 2008 2009 2008 ---- ---- ---- ---- (Unaudited) (Unaudited) Revenue: Collaboration revenue-related party $1,500,000 $2,544,868 $1,500,000 $4,310,551 Collaboration revenue-other 12,500 46,372 25,000 583,872 License and other revenue 2,000,000 - 2,211,547 - --------- --------- --------- --------- Total revenues 3,512,500 2,591,240 3,736,547 4,894,423 Operating expenses: Research and development 3,448,685 8,262,604 7,712,836 17,005,499 General and administrative 1,994,903 3,235,061 4,349,916 6,501,190 Restructuring charges 532 4,876,746 1,863,393 5,197,520 --------- --------- --------- --------- Total operating expenses 5,444,120 16,374,411 13,926,145 28,704,209 --------- ---------- ---------- ---------- Loss from operations (1,931,620) (13,783,171) (10,189,598) (23,809,786) Interest income 6,000 269,385 18,812 729,797 Interest expense (375) (54,433) (987) (113,806) Other income (expense), net (20,952,469) (199) (21,070,126) 472 ----------- ----------- ----------- ------
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences